Local Anesthetics in Special Populations

Local Anesthetics in Special Populations

Local Anesthetics in Special Populations

On this page

LA in Special Groups - The Ground Rules

  • Altered pharmacokinetics: Expect changes in absorption, distribution (e.g., altered Vd), metabolism (↓ hepatic/renal clearance), and excretion.
  • Altered pharmacodynamics: Nerve sensitivity is often ↑ (e.g., elderly, pregnancy), affecting LA potency/duration.
  • Guiding principles:
    • Adopt "start low, go slow" dosing.
    • Crucial: meticulous monitoring for early CNS/CVS toxicity signs.
    • Proactive dose reduction is key.

⭐ Special populations often have a narrower therapeutic window for LAs, demanding careful titration and heightened vigilance.

Pediatric Patients - Tiny Patients, Big Care

  • Pharmacokinetic Differences:
    • ↑ Volume of distribution (Vd) (larger Extracellular Fluid).
    • ↓ Protein binding (esp. neonates due to ↓ alpha-1-acid glycoprotein) → ↑ free drug fraction.
    • ↓ Hepatic metabolism (immature P450 enzymes).
    • ↓ Renal excretion (immature Glomerular Filtration Rate).
  • Increased Toxicity Risk:
    • Higher susceptibility to systemic toxicity.
    • ⚠️ Prilocaine/Benzocaine: Risk of methemoglobinemia (avoid in infants <6 months).
  • Maximum Recommended Doses (mg/kg):
    AnestheticPlainWith Epinephrine
    Lidocaine3-55-7
    Bupivacaine1.5-22-2.5
    Ropivacaine2-32-3

⭐ Neonates exhibit decreased levels of alpha-1-acid glycoprotein, leading to a higher free fraction of local anesthetics and an increased risk of toxicity.

Geriatric Patients - Golden Years, Gentle Doses

  • Physiological Considerations:
    • Reduced organ function (hepatic, renal) → ↓ LA clearance, ↑ half-life.
    • Decreased lean body mass, increased body fat → ↑ volume of distribution for lipid-soluble LAs.
    • Altered protein binding (↓ albumin) → ↑ unbound, active LA.
    • Increased sensitivity of nervous tissue.
    • Polypharmacy → potential drug interactions.
  • Pharmacokinetic Changes:
    • Slower onset of action.
    • Longer duration of effect.
  • Dosing Strategy: Reduce dose by 20-50%. Titrate slowly.

⭐ Geriatric patients show increased susceptibility to CNS toxicity (e.g., confusion, agitation) and cardiotoxicity from LAs.

Pregnancy & Lactation - Two Lives, One Plan

Physiological changes: ↑ CO, ↑ GFR, ↑ Vd; ↓ protein binding (↑ free drug).

  • ⚠️ Increased sensitivity to LA neurotoxicity & cardiotoxicity (e.g., Bupivacaine).

Placental Transfer:

  • Factors: ↑ lipid solubility, ↓ ionization, ↓ protein binding, ↓ molecular weight (📌 LIMP).
  • Ion trapping: Fetal acidosis traps LAs (weak bases) in ionized form. $pH - pKa = log([A^-]/[HA])$.

⭐ Progesterone increases neuronal sensitivity to local anesthetics during pregnancy.

LA Safety Profile:

SettingPreferred LAsNotes
Labor AnalgesiaBupivacaine, RopivacaineEpidural/spinal; monitor for toxicity
LidocainePerineal infiltration
LactationLidocaine, Bupivacaine, RopivacaineGenerally safe; low milk excretion

Co-morbid Conditions - Tricky Terrains

Co-morbidityLA Choice & Dose AdjustmentKey Precautions & Monitoring
Hepatic DiseaseAmides (e.g., lidocaine): ↓ dose due to impaired metabolism.Monitor for CNS/cardiac toxicity. Esters preferred in severe disease.
Renal DiseaseRepeated doses: caution. Risk of active metabolite accumulation.Monitor for systemic toxicity, esp. with mepivacaine, prilocaine.
Cardiac Disease↓ LA dose. Limit/avoid epinephrine with arrhythmias/ischemia.Arrhythmogenic potential. Continuous ECG. Careful vasoconstrictor use.
Respiratory DiseaseHigh neuraxial/interscalene blocks: use cautiously.Risk of phrenic nerve palsy, respiratory depression. Monitor ventilation.
Pseudocholinesterase Def.Esters (procaine, tetracaine): avoid or drastically ↓ dose.Prolonged LA effect/paralysis. Prefer amides. Monitor neuromuscular function.

High‑Yield Points - ⚡ Biggest Takeaways

  • Pregnancy: Bupivacaine has ↑ cardiotoxicity; Lidocaine (Cat B) safer. Avoid high-dose Prilocaine (methemoglobinemia).
  • Pediatrics: Neonates: ↓ AAG, immature liver. Use precise weight-based dosing. Max lidocaine 4.5 mg/kg.
  • Geriatrics: ↓ clearance necessitates LA dose reduction (e.g., 20-50%).
  • Severe Liver Disease: Reduce amide LA dose significantly; ester LAs are safer.
  • Renal Failure: Amide LA dose often unchanged; active metabolites may accumulate.
  • Pseudocholinesterase Deficiency: Avoid ester LAs (prolonged action); prefer amides.
  • Obesity: Dose LAs based on Ideal Body Weight (IBW) to prevent toxicity.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Local Anesthetics in Special Populations

Test your understanding with these related questions

The anesthetic agent which can cause massive hepatic necrosis?

1 of 5

Flashcards: Local Anesthetics in Special Populations

1/10

Highest blood concentrations of local anesthetic are seen after IV injection f/b _____ injection

TAP TO REVEAL ANSWER

Highest blood concentrations of local anesthetic are seen after IV injection f/b _____ injection

tracheal

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Local Anesthetics in Special Pop... - Free Indian Medical PG